Cell‐free DNA for Down syndrome screening in obese women: Is it a cost‐effective strategy?

2019 ◽  
Vol 40 (2) ◽  
pp. 173-178
Author(s):  
Maeve K. Hopkins ◽  
Lorraine Dugoff ◽  
Celeste Durnwald ◽  
Laura J. Havrilesky ◽  
Sarah Dotters‐Katz
Keyword(s):  
Down Syndrome ◽  
Cost Effective ◽  
Effective Strategy ◽  
Obese Women ◽  
Cell Free Dna ◽  
Cost Effective Strategy ◽  
Free Dna ◽  
Down Syndrome Screening

scholarly journals 902: Cell-free DNA for Down syndrome screening in morbidly obese women: Is it a cost-effective strategy?

2019 ◽  
Vol 220 (1) ◽  
pp. S583-S584
Author(s):  
Maeve Hopkins ◽  
Lorraine Dugoff ◽  
Celeste Durnwald ◽  
Laura Havrilesky ◽  
Sarah Dotters-Katz
Keyword(s):  
Down Syndrome ◽  
Cost Effective ◽  
Morbidly Obese ◽  
Effective Strategy ◽  
Obese Women ◽  
Cell Free Dna ◽  
Cost Effective Strategy ◽  
Free Dna ◽  
Down Syndrome Screening

scholarly journals Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening

2018 ◽  
Vol 48 (4) ◽  
pp. 461-470 ◽  
Author(s):  
Kathryn J. Gray ◽  
Louise E. Wilkins-Haug
Keyword(s):  
Down Syndrome ◽  
Cell Free Dna ◽  
Free Dna ◽  
Down Syndrome Screening

scholarly journals First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA

2013 ◽  
Vol 33 (11) ◽  
pp. 1044-1049 ◽  
Author(s):  
J Johnson ◽  
M Pastuck ◽  
A Metcalfe ◽  
G Connors ◽  
R Krause ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Serum Markers ◽  
Cell Free Dna ◽  
Free Dna ◽  
Down Syndrome Screening

A cost effective strategy to fabricate STA@PF@Cu2O hierarchical structure on wood surface: aimed at superhydrophobic modification

2021 ◽  
Vol 55 (2) ◽  
pp. 565-583
Author(s):  
Ke Zhan ◽  
Quanxiong Lu ◽  
Sengwei Xia ◽  
Congnan Guo ◽  
Sisi Zhao ◽  
...  
Keyword(s):  
Hierarchical Structure ◽  
Wood Surface ◽  
Cost Effective ◽  
Effective Strategy ◽  
Cost Effective Strategy

Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer

2021 ◽  
Vol 72 (1) ◽  
pp. 399-413
Author(s):  
Van K. Morris ◽  
John H. Strickler
Keyword(s):  
Colorectal Cancer ◽  
Precision Medicine ◽  
Residual Disease ◽  
Cost Effective ◽  
Patient Specific ◽  
Blood Draw ◽  
Cell Free Dna ◽  
Free Dna ◽  
Metastatic Setting ◽  
Diagnostic Technology

Patient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly when tumor tissue is difficult to access or serial sampling is necessary. As cfDNA diagnostic technology continues to improve, more innovative applications are anticipated. In this review, we focus on four clinical applications for cfDNA analysis in the management of CRC: detecting minimal residual disease, monitoring treatment response in the metastatic setting, identifying drivers of treatment sensitivity and resistance, and guiding therapeutic strategies to overcome resistance.

A cost effective strategy for managing GI bleeding secondary to peptic ulcer disease

1995 ◽  
Vol 108 (4) ◽  
pp. A18 ◽  
Author(s):  
I Hussain ◽  
WH Farrar ◽  
EJ Sofian ◽  
TF Bader ◽  
JD Strom ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Peptic Ulcer Disease ◽  
Cost Effective ◽  
Effective Strategy ◽  
Gi Bleeding ◽  
Ulcer Disease ◽  
Cost Effective Strategy
Sign in / Sign up

Export Citation Format

Share Document